Thomas Reiner

List of Publications by Year
in descending order

141	6,147	57758	82547
papers	citations	44 h-index	72 g-index

157	157	157	7685
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes. Inorganic Chemistry, 2022, 61, 1456-1470.	4.0	8
2	Principles and Applications of Auger-Electron Radionuclide Therapy. , 2022, , .		0
3	Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation. Scientific Reports, 2022, 12, 6185.	3.3	14
4	PARP-1 expression in melanocytic lesions: towards PARPi-FL based molecular diagnosis of melanoma. , 2022, , .		0
5	Imaging Early-Stage Metastases Using an 18F-Labeled VEGFR-1-Specific Single Chain VEGF Mutant. Molecular Imaging and Biology, 2021, 23, 340-349.	2.6	6
6	Optoacoustic Imaging of Glucagon-like Peptide-1 Receptor with a Near-Infrared Exendin-4 Analog. Journal of Nuclear Medicine, 2021, 62, 839-848.	5.0	7
7	[18F]PARPi Imaging Is Not Affected by HPV Status In Vitro. Molecular Imaging, 2021, 2021, 1-10.	1.4	2
8	Bimodal Imaging of Mouse Peripheral Nerves with Chlorin Tracers. Molecular Pharmaceutics, 2021, 18, 940-951.	4.6	3
9	A modular approach toward producing nanotherapeutics targeting the innate immune system. Science Advances, 2021, 7, .	10.3	20
10	REPLY TO LETTER TO THE EDITOR: POTENTIAL USE OF RADIOLABELED ANTIBODIES FOR IMAGING AND TREATMENT OF COVID-19. Journal of Nuclear Medicine, 2021, 62, jnumed.121.261950.	5.0	0
11	Auger: The future of precision medicine. Nuclear Medicine and Biology, 2021, 96-97, 50-53.	0.6	14
12	A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3618-3630.	6.4	21
13	Pharmacological Inhibition of the Voltage-Gated Sodium Channel NaV1.7 Alleviates Chronic Visceral Pain in a Rodent Model of Irritable Bowel Syndrome. ACS Pharmacology and Translational Science, 2021, 4, 1362-1378.	4.9	10
14	Sensors and Inhibitors for the Detection of Ataxia Telangiectasia Mutated (ATM) Protein Kinase. Molecular Pharmaceutics, 2021, 18, 2470-2481.	4.6	7
15	Rapid detection of SARS-CoV-2 using a radiolabeled antibody. Nuclear Medicine and Biology, 2021, 98-99, 69-75.	0.6	2
16	PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. Molecular Pharmaceutics, 2021, 18, 3418-3428.	4.6	16
17	Combined PARP1-targeted nuclear contrast and reflectance contrast enhances confocal microscopic detection of basal cell carcinoma. Journal of Nuclear Medicine, 2021, , jnumed.121.262600.	5.0	5
18	Combining PARPi-FL fluorescence and reflectance contrast for improved detection of basal cell carcinoma (BCC). , 2021, , .		0

#	Article	IF	Citations
19	Multimodal Positron Emission Tomography Imaging to Quantify Uptake of ⁸⁹Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. Bioconjugate Chemistry, 2020, 31, 360-368.	3.6	22
20	An ⁸⁹Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor. Journal of Nuclear Medicine, 2020, 61, 433-436.	5.0	25
21	Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer. Journal of Nuclear Medicine, 2020, 61, 437-442.	5.0	11
22	TOPKi-NBD: a fluorescent small molecule for tumor imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1003-1010.	6.4	5
23	Multimodality labeling strategies for the investigation of nanocrystalline cellulose biodistribution in a mouse model of breast cancer. Nuclear Medicine and Biology, 2020, 80-81, 1-12.	0.6	12
24	Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Research, 2020, 80, 394-405.	0.9	48
25	Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR. Neuro-Oncology Advances, 2020, 2, vdaa119.	0.7	14
26	Imaging Cardiovascular and Lung Macrophages With the Positron Emission Tomography Sensor ⁶⁴ Cu-Macrin in Mice, Rabbits, and Pigs. Circulation: Cardiovascular Imaging, 2020, 13, e010586.	2.6	32
27	Oncology-Inspired Treatment Options for COVID-19. Journal of Nuclear Medicine, 2020, 61, 1720-1723.	5.0	15
28	Poly(ADP-ribose)polymerase1: A potential molecular marker to identify cancer during colposcopy procedures.. Journal of Nuclear Medicine, 2020, 62, jnumed.120.253575.	5.0	3
29	Optical Imaging Modalities: Principles and Applications in Preclinical Research and Clinical Settings. Journal of Nuclear Medicine, 2020, 61, 1419-1427.	5.0	49
30	Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition. Cell, 2020, 183, 786-801.e19.	28.9	101
31	Leveraging synthetic chlorins for bio-imaging applications. Chemical Communications, 2020, 56, 12608-12611.	4.1	5
32	A oneâ€pot radiosynthesis of [¹⁸F]PARPi. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 419-425.	1.0	6
33	Tumor Targeting by Îł_vÎ²₃-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking. ACS Nano, 2020, 14, 7832-7846.	14.6	69
34	Improved radiosynthesis of 123I-MAPi, an auger theranostic agent. International Journal of Radiation Biology, 2020, , 1-7.	1.8	13
35	Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers. Nature Biomedical Engineering, 2020, 4, 272-285.	22.5	43
36	High-resolution optoacoustic imaging of tissue responses to vascular-targeted therapies. Nature Biomedical Engineering, 2020, 4, 286-297.	22.5	92

#	Article	IF	Citations
37	Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy. Frontiers in Pharmacology, 2020, 11, 170.	3.5	57
38	Fluorescence-guided resection of tumors in mouse models of oral cancer. Scientific Reports, 2020, 10, 11175.	3.3	15
39	Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging. Nuclear Medicine and Biology, 2020, 84-85, 80-87.	0.6	12
40	PET/CT Imaging with an 18F-Labeled Galactodendritic Unit in a Galectin-1â€“Overexpressing Orthotopic Bladder Cancer Model. Journal of Nuclear Medicine, 2020, 61, 1369-1375.	5.0	4
41	Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer. Clinical Cancer Research, 2020, 26, 3110-3116.	7.0	36
42	Probing myeloid cell dynamics in ischaemic heart disease by nanotracer hot-spot imaging. Nature Nanotechnology, 2020, 15, 398-405.	31.5	42
43	Targeted Brain Tumor Radiotherapy Using an Auger Emitter. Clinical Cancer Research, 2020, 26, 2871-2881.	7.0	69
44	Fluorescence labeling of a NaV1.7-targeted peptide for near-infrared nerve visualization. EJNMMI Research, 2020, 10, 49.	2.5	10
45	Smartphone epifluorescence microscopy for cellular imaging of fresh tissue in low-resource settings. Biomedical Optics Express, 2020, 11, 89.	2.9	19
46	Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species. Science Translational Medicine, 2019, 11, .	12.4	51
47	Fluorescence Imaging of Peripheral Nerves by a Na_v1.7-Targeted Inhibitor Cystine Knot Peptide. Bioconjugate Chemistry, 2019, 30, 2879-2888.	3.6	20
48	Positron-Emission Tomographic Imaging of a Fluorine 18â€“Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patientâ€“Derived Xenografts. Journal of Thoracic Oncology, 2019, 14, 1743-1752.	1.1	14
49	Acid specific dark quencher QC1 pHLIP for multi-spectral optoacoustic diagnoses of breast cancer. Scientific Reports, 2019, 9, 8550.	3.3	16
50	Blocking of Glucagonlike Peptide-1 Receptors in the Exocrine Pancreas Improves Specificity for Î²-Cells in a Mouse Model of Type 1 Diabetes. Journal of Nuclear Medicine, 2019, 60, 1635-1641.	5.0	14
51	Novel latonduine derived proligands and their copper(<scp>ii</scp>) complexes show cytotoxicity in the nanomolar range in human colon adenocarcinoma cells and in vitro cancer selectivity. Dalton Transactions, 2019, 48, 10464-10478.	3.3	17
52	Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. Clinical Cancer Research, 2019, 25, 4332-4342.	7.0	24
53	Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC: Cardiovascular Imaging, 2019, 12, 2015-2026.	5.3	66
54	[18F]FE-OTS964: a Small Molecule Targeting TOPK for In Vivo PET Imaging in a Glioblastoma Xenograft Model. Molecular Imaging and Biology, 2019, 21, 705-712.	2.6	8

#	Article	IF	Citations
55	Smartphone-based epifluorescence microscope for fresh tissue imaging. , 2019, , .		0
56	Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nature Biomedical Engineering, 2018, 2, 279-292.	22.5	94
57	Bioorthogonal Masking of Circulating Antibodyâ€“TCO Groups Using Tetrazine-Functionalized Dextran Polymers. Bioconjugate Chemistry, 2018, 29, 538-545.	3.6	35
58	PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a HumanÂAntibody Detects ClinicallyÂRelevant Atherothrombosis. Journal of the American College of Cardiology, 2018, 71, 321-335.	2.8	39
59	Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nature Communications, 2018, 9, 176.	12.8	75
60	Reversible Electroporationâ€“Mediated Liposomal Doxorubicin Delivery to Tumors Can Be Monitored With ⁸⁹Zr-Labeled Reporter Nanoparticles. Molecular Imaging, 2018, 17, 153601211774972.	1.4	21
61	PARP-1â€“Targeted Radiotherapy in Mouse Models of Glioblastoma. Journal of Nuclear Medicine, 2018, 59, 1225-1233.	5.0	51
62	Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib. Journal of Nuclear Medicine, 2018, 59, 1316-1320.	5.0	13
63	Current Practice and Emerging Molecular Imaging Technologies in Oral Cancer Screening. Molecular Imaging, 2018, 17, 153601211880864.	1.4	21
64	Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models. EJNMMI Research, 2018, 8, 59.	2.5	16
65	Leveraging PET to image folate receptor Î± therapy of an antibody-drug conjugate. EJNMMI Research, 2018, 8, 87.	2.5	12
66	Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance. Immunity, 2018, 49, 819-828.e6.	14.3	161
67	Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer. Bioconjugate Chemistry, 2018, 29, 3776-3782.	3.6	15
68	Sonophore-enhanced nanoemulsions for optoacoustic imaging of cancer. Chemical Science, 2018, 9, 5646-5657.	7.4	25
69	Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. Journal of Nuclear Medicine, 2018, 59, 1894-1900.	5.0	36
70	Molecular Imaging and Molecular Imaging Technologies. , 2018, , 3-27.		0
71	Evaluation of [18 F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer. Nuclear Medicine and Biology, 2017, 48, 9-15.	0.6	4
72	Polyglucose nanoparticles with renal elimination and macrophage avidity facilitate PET imaging in ischaemic heart disease. Nature Communications, 2017, 8, 14064.	12.8	118

#	Article	IF	Citations
73	Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models. Cancer Research, 2017, 77, 2112-2123.	0.9	27
74	Development of a New Folate-Derived Ga-68-Based PET Imaging Agent. Molecular Imaging and Biology, 2017, 19, 754-761.	2.6	19
75	Hyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in Atherosclerosis. ACS Nano, 2017, 11, 5785-5799.	14.6	137
76	Imaging-guided revival of nanomedicine?. Nanomedicine, 2017, 12, 89-90.	3.3	3
77	Investigating the Cellular Specificity in Tumors of a Surface-Converting Nanoparticle by Multimodal Imaging. Bioconjugate Chemistry, 2017, 28, 1413-1421.	3.6	13
78	Sonophore labeled RGD: a targeted contrast agent for optoacoustic imaging. Photoacoustics, 2017, 6, 1-8.	7.8	23
79	Integrating nanomedicine and imaging. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2017, 375, 20170110.	3.4	5
80	Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7441-E7449.	7.1	28
81	A Novel Technique for Generating and Observing Chemiluminescence in a Biological Setting. Journal of Visualized Experiments, 2017, , .	0.3	0
82	cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339. Dalton Transactions, 2017, 46, 11925-11941.	3.3	11
83	Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent. Molecular Imaging, 2017, 16, 153601211772378.	1.4	16
84	Specific Binding of Liposomal Nanoparticles through Inverse Electronâ€Demand Dielsâ€“Alder Click Chemistry. ChemistryOpen, 2017, 6, 615-619.	1.9	7
85	Synthesis of a Fluorescently Labeled ⁶⁸Ga-DOTA-TOC Analog for Somatostatin Receptor Targeting. ACS Medicinal Chemistry Letters, 2017, 8, 720-725.	2.8	30
86	A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. Journal of Controlled Release, 2017, 262, 47-57.	9.9	44
87	Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging. Nature Protocols, 2017, 12, 1472-1497.	12.0	19
88	A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines. Journal of Visualized Experiments, 2017, , .	0.3	5
89	Molecular Imaging of PARP. Journal of Nuclear Medicine, 2017, 58, 1025-1030.	5.0	75
90	A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer. Theranostics, 2016, 6, 2267-2277.	10.0	53

#	Article	IF	Citations
91	Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma. PLoS ONE, 2016, 11, e0147752.	2.5	26
92	Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate. Bioconjugate Chemistry, 2016, 27, 1789-1795.	3.6	60
93	Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. Nature Communications, 2016, 7, 11838.	12.8	94
94	Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. Scientific Reports, 2016, 6, 21371.	3.3	58
95	Nearâ€Infrared Intraoperative Chemiluminescence Imaging. ChemMedChem, 2016, 11, 1978-1982.	3.2	5
96	Immune cell screening of a nanoparticle library improves atherosclerosis therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6731-E6740.	7.1	95
97	Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models. Molecular Imaging and Biology, 2016, 18, 386-392.	2.6	70
98	InÂVivo PET Imaging of HDL in MultipleÂAtherosclerosisÂModels. JACC: Cardiovascular Imaging, 2016, 9, 950-961.	5.3	78
99	¹⁸F-Based Pretargeted PET Imaging Based on Bioorthogonal Dielsâ€“Alder Click Chemistry. Bioconjugate Chemistry, 2016, 27, 298-301.	3.6	127
100	Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist. Journal of Nuclear Medicine, 2015, 56, 805-811.	5.0	39
101	Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging. Journal of Visualized Experiments, 2015, , e52335.	0.3	6
102	Development of a clickable bimodal fluorescent/PET probe for in vivo imaging. EJNMMI Research, 2015, 5, 120.	2.5	27
103	PET Imaging of Tumor-Associated Macrophages with ⁸⁹Zr-Labeled High-Density Lipoprotein Nanoparticles. Journal of Nuclear Medicine, 2015, 56, 1272-1277.	5.0	145
104	Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma. Molecular Imaging and Biology, 2015, 17, 848-855.	2.6	66
105	Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Science Advances, 2015, 1, .	10.3	173
106	Radioiodinated PARP1 tracers for glioblastoma imaging. EJNMMI Research, 2015, 5, 123.	2.5	48
107	Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics. Molecular Pharmaceutics, 2015, 12, 3575-3587.	4.6	88
108	Effect of Small-Molecule Modification on Single-Cell Pharmacokinetics of PARP Inhibitors. Molecular Cancer Therapeutics, 2014, 13, 986-995.	4.1	42

#	Article	IF	Citations
109	Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solidâ€Phase Peptide Synthesis. ChemistryOpen, 2014, 3, 48-53.	1.9	24
110	Synthesis of the first radiolabeled ¹⁸⁸Re Nâ€heterocyclic carbene complex and initial studies on its potential use in radiopharmaceutical applications. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 441-447.	1.0	11
111	The inverse electron demand Dielsâ€“Alder click reaction in radiochemistry. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 285-290.	1.0	53
112	Efficient Acidâ€Catalyzed ¹⁸F/¹⁹F Fluoride Exchange of BODIPY Dyes. ChemMedChem, 2014, 9, 1368-1373.	3.2	33
113	A Modular Labeling Strategy for In Vivo PET and Near-Infrared Fluorescence Imaging of Nanoparticle Tumor Targeting. Journal of Nuclear Medicine, 2014, 55, 1706-1711.	5.0	85
114	In Vivo Imaging of GLP-1R with a Targeted Bimodal PET/Fluorescence Imaging Agent. Bioconjugate Chemistry, 2014, 25, 1323-1330.	3.6	47
115	PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging. Neoplasia, 2014, 16, 432-440.	5.3	52
116	Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nature Communications, 2013, 4, 1504.	12.8	172
117	Synthetic strategies for efficient conjugation of organometallic complexes with pendant protein reactive markers. Journal of Organometallic Chemistry, 2013, 744, 82-91.	1.8	9
118	¹⁸F-Labeled-Bioorthogonal Liposomes for In Vivo Targeting. Bioconjugate Chemistry, 2013, 24, 1784-1789.	3.6	74
119	Targeting Cathepsin E in Pancreatic Cancer by a Small Molecule Allows In Vivo Detection. Neoplasia, 2013, 15, 684-IN3.	5.3	36
120	Phenylalanine â€“ a biogenic ligand with flexible Î·6- and Î·6:Î¹1-coordination at ruthenium(ii) centres. Dalton Transactions, 2013, 42, 8692.	3.3	13
121	Metalâ€Conjugated Affinity Labels: A New Concept to Create Enantioselective Artificial Metalloenzymes. ChemistryOpen, 2013, 2, 50-54.	1.9	22
122	A Pretargeted PET Imaging Strategy Based on Bioorthogonal Dielsâ€“Alder Click Chemistry. Journal of Nuclear Medicine, 2013, 54, 1389-1396.	5.0	247
123	Metal-Conjugated Affinity Labels: A New Concept to Create Enantioselective Artificial Metalloenzymes. ChemistryOpen, 2013, 2, 40-40.	1.9	0
124	Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications. Journal of Visualized Experiments, 2013, , e50772.	0.3	0
125	Imaging Therapeutic PARP Inhibition In Vivo through Bioorthogonally Developed Companion Imaging Agents. Neoplasia, 2012, 14, 169-IN3.	5.3	97
126	Efficient ¹⁸Fâ€Labeling of Synthetic Exendinâ€4 Analogues for Imaging Beta Cells. ChemistryOpen, 2012, 1, 177-183.	1.9	38

#	Article	IF	Citations
127	Microfluidic Cell Sorter (Î¼FCS) for Onâ€chip Capture and Analysis of Single Cells. Advanced Healthcare Materials, 2012, 1, 432-436.	7.6	43
128	Bioorthogonal Imaging of Aurora Kinaseâ€…A in Live Cells. Angewandte Chemie - International Edition, 2012, 51, 6598-6603.	13.8	85
129	In Vivo PET Imaging of Histone Deacetylases by ¹⁸F-Suberoylanilide Hydroxamic Acid (¹⁸F-SAHA). Journal of Medicinal Chemistry, 2011, 54, 5576-5582.	6.4	56
130	Specific Pathogen Detection Using Bioorthogonal Chemistry and Diagnostic Magnetic Resonance. Bioconjugate Chemistry, 2011, 22, 2390-2394.	3.6	59
131	Nanoparticle-Mediated Measurement of Targetâ€“Drug Binding in Cancer Cells. ACS Nano, 2011, 5, 9216-9224.	14.6	21
132	Ubiquitous Detection of Gram-Positive Bacteria with Bioorthogonal Magnetofluorescent Nanoparticles. ACS Nano, 2011, 5, 8834-8841.	14.6	127
133	Highâ€Yielding, Twoâ€Step ¹⁸F Labeling Strategy for ¹⁸Fâ€PARP1 Inhibitors. ChemMedChem, 2011, 6, 424-427.	3.2	73
134	Synthesis and In Vivo Imaging of a ¹⁸Fâ€Labeled PARP1 Inhibitor Using a Chemically Orthogonal Scavengerâ€Assisted Highâ€Performance Method. Angewandte Chemie - International Edition, 2011, 50, 1922-1925.	13.8	91
135	Bioorthogonal Probes for Poloâ€like Kinaseâ€…1 Imaging and Quantification. Angewandte Chemie - International Edition, 2011, 50, 9378-9381.	13.8	79
136	Towards Quantitative Catalytic Lignin Depolymerization. Chemistry - A European Journal, 2011, 17, 5939-5948.	3.3	465
137	Accurate measurement of pancreatic islet Î²-cell mass using a second-generation fluorescent exendin-4 analog. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12815-12820.	7.1	121
138	Bioorthogonal Smallâ€Molecule Ligands for PARP1 Imaging in Living Cells. ChemBioChem, 2010, 11, 2374-2377.	2.6	56
139	Î·6-Arene complexes of ruthenium and osmium with pendant donor functionalities. Journal of Organometallic Chemistry, 2010, 695, 2667-2672.	1.8	21
140	Near-Infrared Fluorescent Probe for Imaging of Pancreatic Î² Cells. Bioconjugate Chemistry, 2010, 21, 1362-1368.	3.6	46
141	Side chain functionalized Î·5-tetramethyl cyclopentadienyl complexes of Rh and Ir with a pendant primary amine group. Journal of Organometallic Chemistry, 2009, 694, 1934-1937.	1.8	24